Results 231 to 240 of about 63,887 (261)

Right of first refusal to exclusive technology license to make, use and sell research reagents, kits and tool products developed by licensor's cancer diagnostics business.

1995
openaire   +1 more source

Diagnostic Approach to Evaluating the Cause of a Positive Fecal Occult Blood Test

Ca-A Cancer Journal for Clinicians, 1984
exaly  

Possible Diagnostic Implications in Cancer Research

Ca-A Cancer Journal for Clinicians, 1961
exaly  

First amendment to settlement agreement with royalty due on patented kits of medical reagents for human in vitro and veterinary diagnostic immunoassays, used in conjunction with PPD and TB enhancer.

2004
openaire   +1 more source

Scalene Node Biopsy: Correlation With Other Diagnostic Procedures in 550 Cases

Ca-A Cancer Journal for Clinicians, 1969
exaly  

Exclusive patent and know-how license to use, make, have made, and sell monoclonal reagents, monoclonal radiopharmaceuticals, and test kits for in vivo diagnostic testing for human disorders or diseases.

1982
openaire   +1 more source

Pheochromocytoma: 1. Specificity of Laboratory Diagnostic Tests. 2. Safeguards During Operative Removal

Ca-A Cancer Journal for Clinicians, 1969
exaly  

COMMON FATAL DIAGNOSTIC ERRORS: From Inadequate Examination without Biopsy

Ca-A Cancer Journal for Clinicians, 1956
exaly  

Exclusive patent, technology and know-how license to make, have made, use, import, distribute, sell, and sublicense products, devices, diagnostic kits, prognostic kits, test and research reagents, and software for diagnostic, prognostic, or predictive tests related to breast cancer and for the choice of therapeutic agents for improving the clinical outcome of breast cancer.

2010
openaire   +1 more source

The Cancer-Diagnostic Potential of Uterine Exfoliative Cytology

Ca-A Cancer Journal for Clinicians, 1957
exaly